loading...| Preferred Name |
Durvalumab |
|
| Synonyms |
Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer DURVALUMAB Durvalumab Imfinzi MEDI-4736 MEDI4736 |
|
| Definitions |
A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103194 |
|
| Accepted_Therapeutic_Use_For |
locally advanced or metastatic urothelial carcinoma; unresectable stage III non-small cell lung cancer (NSCLC) |
|
| CAS_Registry |
1428935-60-7 |
|
| code |
C103194 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types. |
|
| Display_Name |
Durvalumab |
|
| FDA_UNII_Code |
28X28X9OKV |
|
| FULL_SYN |
Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer DURVALUMAB Durvalumab Imfinzi MEDI-4736 MEDI4736 |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Durvalumab |
|
| Maps_To |
Durvalumab |
|
| NCI_Drug_Dictionary_ID |
740856 |
|
| PDQ_Closed_Trial_Search_ID |
740856 |
|
| PDQ_Open_Trial_Search_ID |
740856 |
|
| Preferred_Name |
Durvalumab |
|
| prefixIRI |
Thesaurus:C103194 |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance |
|
| UMLS_CUI |
C3641122 |
|
| subClassOf |